Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210838 | 0.87 | NPC1 (0.70) | NPC1RAB9AALDH1A1EPHX1EPHX2 | |
| SCHEMBL10211575 | 0.83 | RAB9A (0.70) | NPC1RAB9AALDH1A1EPHX1EPHX2 | |
| SCHEMBL2753005 | 0.82 | RAB9A (0.70) | NPC1RAB9AALDH1A1EPHX1EPHX2 | |
| SCHEMBL10210791 | 0.82 | EPHX1 (0.64) | NPC1RAB9AALDH1A1EPHX1EPHX2 | |
| SCHEMBL10211623 | 0.81 | TAS1R3 (0.50) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10211634 | 0.80 | NPC1 (0.55) | NPC1RAB9AALDH1A1EPHX1EPHX2 | |
| SCHEMBL24381741 | 0.80 | EPHX1 (0.66) | NPC1RAB9AEPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL10211627 | 0.80 | EPHX1 (0.66) | NPC1RAB9AEPHX1EPHX2SMN1; SMN2 | |
| SCHEMBL10210720 | 0.80 | CNR1 (0.67) | NPC1RAB9AALDH1A1EPHX1EPHX2 | |
| SCHEMBL10212192 | 0.80 | NPC1 (0.68) | NPC1RAB9AALDH1A1EPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | NPC1 1778/4885RAB9A 1841/4885ALDH1A1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.